Literature DB >> 7379440

Interaction between oral propranolol and hydralazine.

A J McLean, H Skews, A Bobik, F J Dudley.   

Abstract

Seven healthy subjects were given oral propranolol (1 mg/kg) alone or in combination with hydralazine 25, 50, or 100 mg on separate occasions. Hydralazine induced variable increases in the peak concentrations (p less than 0.05) and in the area under the propranolol concentration: time curves (p less than 0.02) without change in the recovery of 14 C-propranolol/metabolites in urine or in the systemic clearance of propranolol; i.e., oral hydralazine enhanced the systemic availability of propranolol by alteration of "first-pass" (hepatic) clearance. The results indicate the possibility of change in presystemic clearance without reciprocal change in systemic clearance and also suggest that propranolol or any other high-clearance drug should be administered in fixed relationship to hydralazine and other drugs capable of altering "first-pass" hepatic extraction (either due to alteration in splanchnic blood flow or competitive inhibition of metabolism) if large variations in plasma concentrations are to be avoided.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379440     DOI: 10.1038/clpt.1980.103

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Bronchoconstriction of the asthmatic airway by inhaled and ingested propranolol.

Authors:  K M Latimer; R E Ruffin
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

5.  Drug interactions and beta blockers.

Authors:  L Beeley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-17

6.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Assessment of beta-adrenoceptor antagonists in asthmatic patients.

Authors:  R E Ruffin; E L McIntyre; K M Latimer; H E Ward; A J Crockett; J H Alpers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

8.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

9.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

10.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.